Real-World Clinical Outcomes of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: A Report of Two Cases From Mexico
Cureus · 16.08.2026
DOI: 10.7759/cureus.114629 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cureus, erschienen am 16.08.2026. Verfasst von Grecia Zavala Villafuerte und 2 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine, Tecnológico de Monterrey, Guadalajara, MEX. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Internal Medicine, Tecnológico de Monterrey, Guadalajara, MEX.
- Dermatology, Hospital Regional Valentín Gómez Farías, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Zapopan, MEX.
- Dermatology, Hospital San Javier, Guadalajara, MEX.
Zitieren
APA
Zavala Villafuerte, G., Perez-Romero, A. G., & Crocker Sandoval, A. B. (2026). Real-World Clinical Outcomes of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: A Report of Two Cases From Mexico. Cureus. https://doi.org/10.7759/cureus.114629
Vancouver
Zavala Villafuerte G, Perez-Romero AG, Crocker Sandoval AB. Real-World Clinical Outcomes of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: A Report of Two Cases From Mexico. Cureus. 2026. doi:10.7759/cureus.114629
BibTeX
@article{ZavalaVillafuerte2026,
author = {Zavala Villafuerte, Grecia and Perez-Romero, Ana G and Crocker Sandoval, Ana B},
title = {Real-World Clinical Outcomes of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: A Report of Two Cases From Mexico},
journal = {Cureus},
year = {2026},
doi = {10.7759/cureus.114629}
}
EUVIMED